Patent Application Titled "Double Stranded Rna Targeting 17-Beta Hydroxysteroiddehydrogenase 13 (Hsd17b13) And Methods Of Use Thereof" Published Online (USPTO 20240002857).
In: Gene Therapy Weekly, 2024-01-26, S. 2729-2729
serialPeriodical
Zugriff:
The patent application titled "Double Stranded Rna Targeting 17-Beta Hydroxysteroiddehydrogenase 13 (Hsd17b13) And Methods Of Use Thereof" discusses the use of a specific double-stranded RNA molecule to target the HSD17B13 gene, which is associated with non-alcoholic fatty liver disease. The application provides detailed information on the nucleotide sequences and composition of the molecule, as well as its potential applications in regulating liver lipid homeostasis and metabolism. This document could be useful for researchers studying liver diseases and potential treatments. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Application Titled "Double Stranded Rna Targeting 17-Beta Hydroxysteroiddehydrogenase 13 (Hsd17b13) And Methods Of Use Thereof" Published Online (USPTO 20240002857).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-01-26, S. 2729-2729 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Sonstiges: |
|